Education
About Us
Working with TipRanks
Follow Us
Inozyme Pharma, Inc. (INZY)
:INZY
INZY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.72 - $6.24
Previous CloseN/A
Volume213.66K
Average Volume (3M)521.24K
Market Cap
$58.07M
Enterprise Value$246.12M
Total Cash (Recent Filing)$32.91M
Total Debt (Recent Filing)$6.78M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
May 13, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding64,240,200
10 Day Avg. Volume476,654
30 Day Avg. Volume521,236
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap4.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.57
Forecast
1Y Price Target
$13.29Price Target Upside1445.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Inozyme Pharma News
PremiumCompany Announcements
Inozyme Pharma Focuses on ENPP1 Deficiency Program
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsINZ-701 is in Phase 3 development, indicating progress in clinical trials for ENPP1 Deficiency treatment.
Market OpportunityThe market opportunity for INZ-701 in treating ENPP1 Deficiency is highlighted as a focus area.
Bears Say
Financial PerformanceInozyme reported Q4 results including a $27MM net loss and net cash of $113MM.
Program ChangesDe-prioritization of the ABCC6 and Calciphylaxis programs and a ~25% workforce reduction to conserve cash.
---
Ownership Overview
2.90% Insiders
13.38% Mutual Funds
54.56% Other Institutional Investors
21.19% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INZY FAQ
What was Inozyme Pharma, Inc.’s price range in the past 12 months?
Inozyme Pharma, Inc. lowest stock price was $0.72 and its highest was $6.24 in the past 12 months.
What is Inozyme Pharma, Inc.’s market cap?
Inozyme Pharma, Inc.’s market cap is $58.07M.
When is Inozyme Pharma, Inc.’s upcoming earnings report date?
Inozyme Pharma, Inc.’s upcoming earnings report date is May 13, 2025 which is in 33 days.
How were Inozyme Pharma, Inc.’s earnings last quarter?
Inozyme Pharma, Inc. released its earnings results on Mar 10, 2025. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.406 by -$0.004.
Is Inozyme Pharma, Inc. overvalued?
According to Wall Street analysts Inozyme Pharma, Inc.’s price is currently Undervalued.
Does Inozyme Pharma, Inc. pay dividends?
Inozyme Pharma, Inc. does not currently pay dividends.
What is Inozyme Pharma, Inc.’s EPS estimate?
Inozyme Pharma, Inc.’s EPS estimate is -0.41.
How many shares outstanding does Inozyme Pharma, Inc. have?
Inozyme Pharma, Inc. has 64,240,200 shares outstanding.
What happened to Inozyme Pharma, Inc.’s price movement after its last earnings report?
Inozyme Pharma, Inc. reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.406. Following the earnings report the stock price went down -7.826%.
Which hedge fund is a major shareholder of Inozyme Pharma, Inc.?
Currently, no hedge funds are holding shares in INZY
---
Inozyme Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.29 (1445.35% Upside)
$13.29 (1445.35% Upside)
Blogger Sentiment
Bullish
INZY Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 12.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.43%
12-Months-Change
Fundamentals
Return on Equity
-102.90%
Trailing 12-Months
Asset Growth
-38.67%
Trailing 12-Months
Company Description
Inozyme Pharma, Inc.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
---
INZY Stock 12 Month Forecast
Average Price Target
$13.29
▲(1445.35% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Rocket Pharmaceuticals
―
Seres Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering INZY
1 Year
1 Year Success Rate
13/26 ratings generated profit
1 Year Average Return
-0.63%
reiterated a buy rating last month
Copying Edward White's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -0.63% per trade.
---